 | |
| Clinical data | |
|---|---|
| Other names | WIN 55,225 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C25H24N2O2 |
| Molar mass | 384.479 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
JWH-200 (WIN 55,225[1]) is ananalgesic chemical from theaminoalkylindole family that acts as acannabinoid receptor agonist. Itsbinding affinity,Ki at the CB1 receptor is 42 nM, around the same as that ofTHC,[2] but its analgesic potencyin vivo was higher than that of other analogues with stronger CB1 binding affinityin vitro,[3] around 3 times that of THC but with less sedative effect,[4] most likely reflecting favourablepharmacokinetic characteristics. It was discovered in 1991 bySterling Drug as a potentialanalgesic following the earlier identification of related compounds such aspravadoline andWIN 55,212-2.[5]
JWH-200 is considered a Schedule 9 prohibited substance in Australia under thePoisons Standard (October 2015).[6] A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.[6]
In July 2015, JWH-200 became a controlled substance in Canada.[7]
The USDEA temporarily declared JWH-200 aschedule I controlled substance on 1 March 2011 through 76 FR 11075, and permanently instated the same schedule on 9 July 2012 in the Section 1152 of theFood and Drug Administration Safety and Innovation Act.[8]
JWH-200 has been classified under theBtMG as Anlage II.[9]
